drugset / Trial / NCT06162351
A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Single arm phase II study for with primary objective to evaluate the efficacy of PLX038 on response rate for patients with pretreated, metastatic or locally advanced triple negative breast cancer.
Timeline
- Start
- 2024-04-17
- Primary completion
- 2025-05-15
- Completion
- 2025-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DFP-13318 | Other / unclassified | 1730 mg/m2 | Intravenous |